Finding and targeting drug-resistant cells in small cell lung cancer
Official title: Detection and elimination of drug tolerant persister cells in small cell lung cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11102388 · Data updated 2026-11-12
This study is looking at small cell lung cancer to find ways to target stubborn cells that make the cancer hard to treat, with the hope of developing better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | April 11, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $424,836 |
| NIH project number | 1R01CA299261-01 |
| Project ID | NIH-11102388 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with small cell lung cancer who are undergoing or have undergone treatment.
✕Less likely to help
Patients with other types of lung cancer or those who are not currently receiving treatment for small cell lung cancer may not benefit from this research.
What this research studies
This research focuses on small cell lung cancer (SCLC), a type of cancer known for its aggressive nature and tendency to recur after initial treatment. The project aims to identify and eliminate drug-tolerant persister cells (DTPCs) that contribute to the cancer's resistance to therapy. By utilizing a collection of patient samples and advanced models, the research team will explore the mechanisms behind the cancer's response to treatment and its subsequent resistance. Patients may benefit from new strategies that specifically target these resistant cells, potentially leading to more effective treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for small cell lung cancer patients by effectively targeting drug-resistant cancer cells.
How similar studies have gone: Previous research has shown promise in targeting drug-resistant cancer cells, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Gay, Carl Michael — University of Tx Md Anderson Can Ctr
- Study coordinator: Gay, Carl Michael
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.